Inter-observer agreement in endoscopic scoring systems: Preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD)

Digestive and Liver Disease

Volumn 46, Issue 11, 2014, Pages 969-973

  Daperno, Marco ^a   Comberlato, Michele ^b   Bossa, Fabrizio ^c   Biancone, Livia ^d   Bonanomi, Andrea G ^e   Cassinotti, Andrea ^f   Cosintino, Rocco ^g   Lombardi, Giovanni ^h   Mangiarotti, Roberto ^g   Papa, Alfredo ⁱ   Pica, Roberta ^j   Rizzello, Fernando ^k   D'Incà, Renata ^l   Orlando, Ambrogio ^m  

^a Gastroenterology Unit Mauriziano Hospital Turin   (Italy)

^b CENTRAL HOSPITAL OF BOLZANO   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^h CARDARELLI HOSPITAL   (Italy)

ⁱ CATHOLIC UNIVERSITY   (Italy)

^j SANDRO PERTINI HOSPITAL   (Italy)

^k UNIVERSITY OF BOLOGNA   (Italy)

^l UNIVERSITY OF PADOVA   (Italy)

^m United Hospitals Villa Sofia Cervello   (Italy)

more..

Author keywords

CDEIS; Endoscopic scores; Interobserver agreement; Mayo endoscopic subscore; Rutgeerts' score; SES CD

Indexed keywords

ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ENDOSCOPIC INDEX OF SEVERITY; GASTROENTEROLOGIST; HUMAN; INTESTINE ENDOSCOPY; JOB EXPERIENCE; MAYO SUBSCORE FOR ULCERATIVE COLITIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NORMAL HUMAN; REPRODUCIBILITY; RUTGEERTS SCORE; SCORING SYSTEM; SIMPLE ENDOSCOPIC SCORE CROHN DISEASE; ULCERATIVE COLITIS; VIDEORECORDING; COLITIS, ULCERATIVE; EVALUATION STUDY; FEMALE; GASTROENTEROLOGY; GASTROINTESTINAL ENDOSCOPY; HEALTH CARE QUALITY; INFLAMMATORY BOWEL DISEASES; INFORMATION PROCESSING; ITALY; MALE; OBSERVER VARIATION; PATHOLOGY; PROCEDURES; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; STANDARDS; TRENDS;

CORTICOSTEROID;

ADRENAL CORTEX HORMONES; COLITIS, ULCERATIVE; CROHN DISEASE; DATA COLLECTION; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTROENTEROLOGY; HUMANS; INFLAMMATORY BOWEL DISEASES; ITALY; MALE; OBSERVER VARIATION; PROCESS ASSESSMENT (HEALTH CARE); QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 84908254016     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.07.010     Document Type: Article

References (45)

1. Dignass A., Van Assche G., Lindsay J.O., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. Journal of Crohn's and Colitis 2010, 4:28-62.
2. Dignass A., Lindsay J.O., Sturm A., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: Current management. Journal of Crohn's and Colitis 2012, 6:991-1030.
3. Annese V., Daperno M., Rutter M.D., et al. European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn's and Colitis 2013, 7:982-1018.
4. Magro F., Langner C., Driessen A., et al. European consensus on the histopathology of inflammatory bowel disease. Journal of Crohn's and Colitis 2013, 7:827-851.
5. Rutgeerts P., Geboes K., Vantrappen G., et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99:956-963.
6. Allez M., Lemann M., Bonnet J., et al. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. American Journal of Gastroenterology 2002, 97:947-953.
7. Froslie K.F., Jahnsen J., Moum B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
8. Wright E.K., De Cruz P.P., Kamm M.A., et al. Intestinal resection in Crohn's disease is associated with significant and durable improvement in health related quality of life although to a lesser extent in women and smokers. Results from the POCER study. Journal of Crohn's and Colitis 2014, DOP086.
9. Carbonnel F., Lavergne A., Lémann M., et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Digestive Diseases and Sciences 1994, 39:1550-1557.
10. Travis S.P., Farrant J.M., Ricketts C., et al. Predicting outcome in severe ulcerative colitis. Gut 1996, 38:905-910.
11. Daperno M., Sostegni R., Scaglione N., et al. Outcome of a conservative approach in severe ulcerative colitis. Digestive and Liver Disease 2004, 36:21-28.
12. Solberg I.C., Lygren I., Jahnsen J., et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scandinavian Journal of Gastroenterology 2009, 44:431-440.
13. Rutgeerts P., Diamond R.H., Bala M., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy 2006, 63:433-442. quiz 464.
14. Rutgeerts P., Van Assche G., Sandborn W.J., et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012, 142. 1102-11.e2.
15. Hebuterne X., Lemann M., Bouhnik Y., et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013, 62:201-208.
16. Baert F., Moortgat L., Van Assche G., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468. quiz e10-1.
17. Ardizzone S., Cassinotti A., Duca P., et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clinical Gastroenterology and Hepatology 2011, 9. 48-9.e3.
18. Colombel J.F., Rutgeerts P., Reinisch W., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011, 141:1194-1201.
19. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 2005, 353:2462-2476.
20. Sandborn W.J., van Assche G., Reinisch W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012, 142. 257-65.e1-3.
21. Sandborn W.J., Feagan B.G., Marano C., et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014, 146. 96-109.e1.
22. Sandborn W.J., Feagan B.G., Marano C., et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014, 146:85-95. quiz e14-5.
23. Feagan B.G., Rutgeerts P., Sands B.E., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 2013, 369:699-710.
24. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine 1987, 317:1625-1629.
25. Mary J.Y., Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study, Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989, 30:983-989.
26. Daperno M., D'Haens G., Van Assche G., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointestinal Endoscopy 2004, 60:505-512.
27. Samuel S., Bruining D.H., Loftus E.V., et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clinical Gastroenterology and Hepatology 2013, 11. 49-54.e1.
28. Travis S.P., Schnell D., Krzeski P., et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 2013, 145:987-995.
29. Osada T., Ohkusa T., Yokoyama T., et al. Comparison of several activity indices for the evaluation of endoscopic activity in UC: inter- and intraobserver consistency. Inflammatory Bowel Diseases 2010, 16:192-197.
30. Feagan B.G., Sandborn W.J., D'Haens G., et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013, 145. 149-57.e2.
31. Khanna R., Zou G., D'Haens G., et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis 2014, 8(Suppl. 1):S13-S14.
32. Fleiss J.L., Levin B., Paik M.C. The measurement of interrater agreement. Statistical methods for rates and proportions 2004, John Wiley & Sons, Inc., Hoboken, NJ, USA. 3rd ed., 10.1002/0471445428.ch18.
33. McGraw K.O., Wong S.P. Forming inferences about some intraclass correlation coefficients. Psychological Methods 1996, 1:30-46.
34. Travis S.P., Schnell D., Krzeski P., et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012, 61:535-542.
35. Thia K.T., Loftus E.V., Pardi D.S., et al. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflammatory Bowel Diseases 2011, 17:1257-1264.
36. https://www.tga.gov.au/pdf/euguide/ewp1846306en.pdf.
37. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine 2010, 362:1383-1395.
38. Florent C., Cortot A., Quandale P., et al. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology and Hepatology 1996, 8:229-233.
39. Ewe K., Bottger T., Buhr H.J., et al. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial, German Budesonide Study Group. European Journal of Gastroenterology and Hepatology 1999, 11:277-282.
40. Hanauer S.B., Korelitz B.I., Rutgeerts P., et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004, 127:723-729.
41. Rutgeerts P., Van Assche G., Vermeire S., et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005, 128:856-861.
42. D'Haens G.R., Vermeire S., Van Assche G., et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008, 135:1123-1129.
43. Reinisch W., Angelberger S., Petritsch W., et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010, 59:752-759.
44. Orlando A., Mocciaro F., Renna S., et al. Early post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. J Crohns Colitis 2014, pii: S1873-9946(14)00059-2 [Epub ahead of print]. 10.1016/j.crohns.2014.02.010.
45. Ferrante M., Colombel J.F., Sandborn W.J., et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology 2013, 145. 978-86.e5.